FDA Grants Full Approval to Eisai’s Alzheimer’s Drug
- July 07, 2023
The Food and Drug Administration (FDA) gave July 6 its full approval to Eisai Co. and Biogen Inc.’s drug lecanemab-irmb, a monoclonal antibody with the brand name Leqembi™, for treating Alzheimer’s disease.
ARTICLE TAGS
You must be logged in to access this content.